NeuroPace

What new development or research in epilepsy care are you most optimistic about? Share your thoughts below. 
#NEAM2025 #EpilepsyAwarenessMonth #AllinForEpilepsy

Today and every day, we are thankful for the dedicated medical professionals who commit their lives to caring for the epilepsy community. Thank you for all you do. Progress is built on collaboration. Your clinical expertise, tireless commitment, and partnership are what make life-changing outcomes possible. We are honored to be your partners in this work. From the entire NeuroPace team, we wish you a well-deserved and restful Thanksgiving.

#NEAM2025 #EpilepsyAwarenessMonth #AllinForEpilepsy

Helping patients identify and manage seizure triggers is a key component of a comprehensive management strategy. What are the most common triggers you see in your practice? #NEAM2025 #EpilepsyAwarenessMonth #AllinForEpilepsy #SeizureTriggers

The comorbidity of epilepsy and mental health challenges is well-documented. A holistic care plan that addresses both physical and mental well-being is essential for improving quality of life. #NEAM2025 #EpilepsyAwarenessMonth #AllinForEpilepsy

Don't miss the preliminary NAUTILUS Study 18-month results of the RNS System responsive thalamic stimulation for the treatment of idiopathic generalized epilepsy (IGE) and get a first look at NeuroPace AI tools at AES 2025. Sunday, Dec 7, 2:30–3:30 p.m. in the Exhibit Hall. Add Product Theater to Calendar - https://bit.ly/43ADSmy

82% Median Seizure Reduction at 3 Years This AES, get the full picture. The PAS Study—the largest FDA-reviewed neuromodulation study for drug-resistant focal epilepsy—shows sustained, long-term outcomes: 82% median seizure reduction at 3 years, outperforming other neuromodulation therapies. 🔗 Register for one of our events or stop by booth #125 to learn more https://bit.ly/3JXhL35 Important Safety Information: https://lnkd.in/g6a9exs NOTE: Therapies were studied using different study designs. Caution must be exercised when comparing results. 1. RNS System Post-approval Study Oral Presentation, American Academy of Neurology, April 2025, all outcomes are ITT, median seizure reduction is observed case data. 2. Morris et al, Neurology, 1999 3. Kaufmann et al., Epilepsia, 2024

📢📊 New IGE data at #AES2025! Get the 18-month preliminary results from the NAUTILUS Study at AES: https://lnkd.in/gSPZGYPC. NAUTILUS is the only randomized controlled study to evaluate neuromodulation therapy for idiopathic generalized epilepsy. Plus, learn how NeuroPace is exploring the use of AI to develop next-generation tools that drive innovation in epilepsy care. CAUTION - Investigational device. Limited by US law to investigational use for IGE. 🗓 Sunday, Dec 7th, 2:30 p.m. - 3:30 p.m. 📍 Product Theater in the Exhibit Hall Add to calendar: https://lnkd.in/gSPZGYPC

Join the AES Fellows Networking Reception. Connect with peers and hiring directors over cocktails. Learn how the RNS® System iEEG data informs seizure medication management, hosted by Dr. Morrell & Dr. Dugan. Register here: https://bit.ly/4a2vlwu Important Safety Information: https://lnkd.in/g6a9exs

82% Median Seizure Reduction at 3 Years The RNS System doesn’t just help reduce seizures—it helps patients reclaim their daily lives. The RNS® System delivers sustained seizure control over time. The PAS study—the largest FDA-reviewed prospective neuromodulation study for drug-resistant epilepsy—demonstrates 82% median seizure reduction at 3 years. 📍 Stop by Booth #125 at AES 2025 to learn more. 🔗 From data to discussion - experience NeuroPace at AES: https://bit.ly/49SBICz Important Safety Information: https://lnkd.in/g6a9exs 1. RNS System Post-approval Study Oral Presentation, American Academy of Neurology, April 2025, all outcomes are ITT, median seizure reduction is observed case data.

Refine your skills in PDMS, Simple Set, and long-term therapy strategies. Optimize patient outcomes with RNS® programming. Register today: https://bit.ly/4peGA9J Important Safety Information: https://lnkd.in/g6a9exs